



Express Mail No. EV 335 856 905 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Möhler *et al.* Confirmation No.: 5224
Serial No.: 09/972,799 Art Unit: 1647
Filed: October 5, 2001 Examiner: Robert S. Landsman
For: SELECTIVE ANXIOLYTIC Attorney Docket No: 9261-005
THERAPEUTIC AGENTS

SEP 12 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER CFR § 1.56 AND § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office ("PTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached revised PTO 1449 form entitled "List of References Cited by Applicant."

References A01, B01 and C01-C08 are listed on the attached revised form PTO 1449.

A copy of each of references A01, B01 and C01-C08 is submitted herewith.

Identification of the submitted references is not to be construed as an admission by Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97 (b)(3), because this Information Disclosure Statement is being submitted prior to the mailing date of a first Office Action on the merits, no fee is believed to be due. However, if the Patent and Trademark Office determines otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16 1150. A duplicate of this sheet is enclosed

for accounting purposes.

Date: September 8, 2003

Respectfully submitted,

Thomas E. Friebel

by [Signature]
REC'D NO 40, 207

29,258

Thomas E. Friebel

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT <i>OIP Use several sheets if necessary</i>		ATTY. DOCKET NO. 9261-005	APPLICATION NO. 09/972,799
<i>SEP 08 2003</i>		APPLICANT Möhler et al.	RECEIVED <i>SEP 12 2003</i>
		FILING DATE October 5, 2001	GROUP 1647 PCT CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,652,100	7/29/97	Hadingham et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B01	WO 98/19165	5/07/98	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Crestani et al., 2001, "GABA _A receptor subtype-specific mediation of benzodiazepine actions." Naunyn-Schmiedeberg's Archives of Pharmacology 363(4):R87.
C02	Bonetti et al., 1988, "Ro 15-4513: Partial Inverse Agonism at the BZR and Interaction with Ethanol." Pharmacol. Biochem. Behav. 3:733-49.
C03	Martin and Lattmann, 1999, "Benzodiazepine recognition site ligands and GABA _A receptors." Exp. Opin. Ther. Patents 9(10):1347-1358.
C04	McKernan et al., 2000, "Sedative but not anxiolytic properties of benzodiazepine are mediated by GABA _A receptor α_1 subtype." Nature Neuroscience 3(6):587-592.
C05	Möhler et al., 1996, Chapter 3, <u>Ion channels</u> , Vol. 4, Ed: Toshio Narahashi, Plenum Press, New York, pp. 89-113.
C06	Möhler et al., 2001, "GABA _A -receptor subtypes: a new pharmacology." Curr. Opin. Pharmacol. 2:22-25.
C07	Shader and Greenblatt, 1993, "Use of benzodiazepines in anxiety disorders." N. Engl. J. Med. 328(19):1398-405.
C08	Rudolph et al., 1999, "Benzodiazepine actions mediated by specific γ -aminobutyric acid _A receptor subtypes," Nature 401:796-800.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not
 in conformance and not considered. Include copy of this form with next communication to applicant.